Planning to receive at least 4 cycles of adjuvant or neoadjuvant chemotherapy

Medically eligible to safely receive adjuvant or neoadjuvant chemotherapy and pegfilgrastim as determined by the investigator

Planning to receive prophylaxis with pegfilgrastim starting in the first cycle and continuing throughout each chemotherapy cycle of the study period

Has provided informed consent

Able to understand the content of the DVD material, in investigator's opinion

Able to read and understand English

Exclusion Criteria

Planning to receive weekly chemotherapy

Chronic use of oral NSAIDs or oral antihistamines with the following exception:

- Chronic oral aspirin use for cardiovascular-related indications

Ongoing chronic pain, or other painful conditions requiring treatment (including immediate post-operative treatment of surgical or procedural-associated pain) as determined by the investigator

Chronic oral steroid use. Premedication related to the administration of taxanes, and use of anti-emetics is allowed, per usual clinical practice.

Prior chemotherapy treatment for cancer within 5 years of current breast cancer diagnosis

Prior use of G-CSF

Currently enrolled in, or less than 30 days since ending, another clinical trial which includes language directing G-CSF (filgrastim, pegfilgrastim, other) or GM-CSF (sargramostim) use

Currently enrolled in, or less than 30 days since ending, another interventional clinical trial which includes a blinded treatment or blinded treatment arm (whether or not the subject is randomized to the blinded arm)

Currently enrolled in, or less than 30 days since ending, another interventional clinical trial which includes the use of any agent not currently considered to be standard therapy for the adjuvant or neoadjuvant treatment of stage I-III breast cancer based on NCCN Clinical Practice Guidelines in Oncology for Breast Cancer

Currently enrolled in, or less than 30 days since ending, any pain intervention study

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01752907